BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Praecis Pharmaceuticals Incorporated (PRCS) Presents Preclinical Data On PPI-2458


10/18/2006 11:13:31 AM

WALTHAM, Mass.--(BUSINESS WIRE)--PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it is presenting preclinical data on its investigational compound, PPI-2458, at the 14th International Inflammation Research Association Conference being held in Cambridge, Maryland. The Company’s presentation, entitled “Disease-modifying activity in a model of rheumatoid arthritis with an orally available inhibitor of methionine aminopeptidase type-2, PPI-2458,” will be delivered by William Westlin, Ph.D., Senior Vice President, Preclinical Research today at 3:00 p.m., EDT. Dr. Westlin will present preclinical data that provide rationale for studying the investigational compound PPI-2458 as a targeted molecular therapy for rheumatoid arthritis. A copy of the presentation will be posted on the Company’s website at http://www.praecis.com, under “Investors” following the presentation.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES